Thursday, April 04, 2024 10:10:26 AM
And some mistakes are much much harder to fix after the fact:
A) back when they thought they could get premium pricing in aesthetics they decided not to do the Botox strategies to decouple the pricing on the aesthetic side from pricing on the therapeutic side (eg freebies for aesthetics injectors as long as the injectors obeyed rules that were unenforceable) There wasn’t much need if you were getting premium pricing in aesthetics. But then they had to cut aesthetic prices and since it wasn’t decoupled … they eviscerated the pricing in therapeutics.
B) regaining trust of injectors who thought that they could just use it the same as Botox and get longer duration easily. Ok, that was naive on the part of the injectors - but that’s still mostly a Revance Big Boy problem. They should have known that wasn’t possible and been clear on this - while setting up a system to allow lesson sharing. Note: they really need to be transparent on this - eg what percent of injectors from 2Q 2023 reordered in Q4? In Q1 2024?
Other areas will be more easily fixed - eg give patient coupons, allow injectors to advertise on price. But other things will be harder to fix.
Recent RVNC News
- Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024 • Business Wire • 05/02/2024 08:05:00 PM
- Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting • Business Wire • 04/12/2024 12:00:00 PM
- Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/27/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:33:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 10:08:05 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/05/2024 10:00:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:34:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:33:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:44:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:33:28 PM
- Revance Announces Pricing of $100.0 Million Public Offering of Common Stock • Business Wire • 03/04/2024 02:25:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 03/04/2024 11:39:11 AM
- Revance Announces Proposed Public Offering of Common Stock • Business Wire • 03/04/2024 11:37:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/29/2024 09:36:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 09:07:18 PM
- Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update • Business Wire • 02/28/2024 09:05:00 PM
- Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024 • Business Wire • 02/21/2024 01:01:00 PM
- Revance to Participate in Upcoming Investor Conferences • Business Wire • 02/21/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 08:45:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:28:38 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 02:39:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 09:04:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:48:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:46:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:45:33 PM
FEATURED NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM